This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?
by Indrajit Bandyopadhyay
OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.
OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?
by Indrajit Bandyopadhyay
OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.
Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?
by Indrajit Bandyopadhyay
DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.
Here's Why HealthStream (HSTM) is Poised for a Turnaround After Losing -13.2% in 4 Weeks
by Zacks Equity Research
HealthStream (HSTM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
HealthStream (HSTM) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
HealthStream (HSTM) delivered earnings and revenue surprises of -12.50% and 1.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Dayforce to Report Q1 Earnings: Buy Now or Wait for Results?
by Zacks Equity Research
Dayforce's Q1 performance is expected to have benefited from strong client retention, AI-led platform enhancements and rising recurring revenue per customer.
Buy These Top-Ranked 5 Stocks to Play an Earnings Beat
by Sanghamitra Saha
Top-ranked stocks Fox (FOXA), Newmont (NEM), Affirm (AFRM), HealthStream (HSTM)) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases.
JKHY Gears Up to Report Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Jack Henry and Associates' third-quarter fiscal 2025 results are likely to benefit from higher sales across all its segments.
DoorDash, Inc. (DASH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
DoorDash (DASH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alphabet (GOOGL) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Alphabet (GOOGL) delivered earnings and revenue surprises of 39.11% and 1.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
HealthStream (HSTM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
HealthStream (HSTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why HealthStream (HSTM) Could Beat Earnings Estimates Again
by Zacks Equity Research
HealthStream (HSTM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BIDU or HSTM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BIDU vs. HSTM: Which Stock Is the Better Value Option?
All You Need to Know About HealthStream (HSTM) Rating Upgrade to Buy
by Zacks Equity Research
HealthStream (HSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
HealthStream (HSTM) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
HealthStream (HSTM) delivered earnings and revenue surprises of 23.08% and 0.92%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
HSTM or ZS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSTM vs. ZS: Which Stock Is the Better Value Option?
HealthStream, Inc. (HSTM) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
HealthStream (HSTM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
HealthStream, Inc. (HSTM) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
HealthStream (HSTM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
New Strong Buy Stocks for October 31st
by Zacks Equity Research
HSTM, MATX, ORLA, MCO and LUV have been added to the Zacks Rank #1 (Strong Buy) List on October 31, 2024.
HealthStream (HSTM) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
HealthStream (HSTM) delivered earnings and revenue surprises of 58.33% and 0.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
HSTM vs. ZS: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSTM vs. ZS: Which Stock Is the Better Value Option?
New Strong Buy Stocks for July 26th
by Zacks Equity Research
FISI, BTE, HSTM, WDC and VIRC have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2024.
Best Momentum Stocks to Buy for July 26th
by Zacks Equity Research
HSTM, WDC and BTE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 26, 2024.
HealthStream (HSTM) Q2 Earnings Top Estimates
by Zacks Equity Research
HealthStream (HSTM) delivered earnings and revenue surprises of 16.67% and 1.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Dropbox (DBX) Stock Jumps 5.6%: Will It Continue to Soar?
by Zacks Equity Research
Dropbox (DBX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.